Search

Around the globe, thousands of people worldwide are suffering by Parkinson’s Disease (PD), a central nervous system degenerative condition. Early detection and diagnosis of PD is crucial for successful treatment and management of the disease. In past few years, Machine learning (ML) algorithms has shown great potential in predicting PD based on various physiological and neurological markers. In this disease prediction system, a system is proposed using ML-based approach to predict the presence of PD in patients. The system employs various machine learning models, including Gradient Boosted Tree, random forest, and logistic regression, to identify key markers and patterns associated with the disease. Overall, this disease prediction system provides a valuable tool for early detection and diagnosis of PD, which can lead to better management and treatment of the disease. The proposed approach can also be extended to other neurological disorders, providing a general framework for disease prediction and diagnosis.

Objectives Community-acquired pneumonia (CAP) is a significant source of hospital admissions and mortality. Atypical organisms are implicated in up to 40% of cases of CAP diagnoses. We studied the difference in outcomes of severe CAP patients treated with doxycycline versus azithromycin in addition to β-lactam therapy. Patients and methods This was a prospective observational cohort study from March 2020 to July 2022 in a medical ICU (MICU) of an academic quaternary medical center. Adults ≥18 years admitted to the MICU receiving doxycycline or azithromycin in addition to β-lactam therapy for the treatment of CAP were included for analysis. The primary outcomes were in-hospital and 30 day mortality. Secondary outcomes were ICU and hospital length-of-stay, 30 day readmission, days of mechanical ventilation, escalation and duration of antibiotics, adverse effects such as Clostridioides difficile infection and QTc prolongation. Results Sixty-three patients were in the azithromycin group and eighty-six patients in the doxycycline group. Both groups had similar APACHE IV and CURB-65 scores. The mean Charlson Comorbidity Index score was higher for the doxycycline group compared with the azithromycin group (P  = 0.04). There was no statistically significant difference in in-hospital and 30 day mortality between the groups (P  = 0.53, P  = 0.57). There were no significant differences in any of the secondary outcomes. Conclusions MICU patients with severe CAP who received doxycycline versus azithromycin in addition to β-lactam treatment showed no significant differences in outcomes. These data offer support for inclusion of doxycycline as an alternative regimen in current IDSA recommendations. [ABSTRACT FROM AUTHOR]

It is estimated that about 25% of humanity is infected with the bacterium Mycobacterium tuberculosis. That is about 2 billion people. Several new vaccines will pass Phase I clinical trials in the next few years. This paper briefly summarizes past and present challenges to developing a vaccine against tuberculosis as well as treating tuberculosis. TB is a pathogen that infects more individuals globally than any other communicable disease. TB is particularly devastating in poor developing countries, notably in Africa and Southeast Asia. Despite the WHO's efforts to overcome TB, Multi Drug Resistant (MDR) TB and Extremely Drug Resistant (XDR) TB are huge challenges. [ABSTRACT FROM AUTHOR]

An essay is presented on the relationship between the religion and the common law during England's early modern phase and also discusses the work of a lawyers including John Sadler, Herbert Butterfield, Alan Cromartie and, Reid Barbour to understand this link better.